- Fluor Corp (NYSE:FLR) reported a first-quarter FY23 revenue growth of 20% year-over-year to $3.75 billion, beating the consensus of $3.55 billion.
- Sales by segment: Energy Solutions $1.61 billion (+37.3% Y/Y), Urban Solutions $1.21 billion (+13.9% Y/Y), Mission Solutions $649 million (+9.4% Y/Y) and Others $283 million (-3.7% Y/Y).
- FLR recorded a total segment loss of $(15) million, compared to a profit of $115 million in 1Q22.
- Net loss attributable to Fluor of $(107) million reflects project forecast revisions and sale of AMECO South America.
- Adjusted EPS improved to $0.28 from $0.16 in 1Q22, missed the consensus of $0.37.
- Adjusted EBITDA decreased by 21.1% Y/Y to $71 million, and the margin fell by 100 bps to 1.9%.
- New awards in Q1 totaled $3.23 billion, up from $1.93 billion a year ago. Consolidated backlog was $25.62 billion as of March 31, 2023.
- At the end of the quarter, Fluor’s cash and marketable securities were $2.3 billion, including $268 million held by NuScale.
- FY23 Outlook, reaffirmed: Fluor sees FY23 adjusted EPS of $1.50-$1.90 (consensus $1.66) and Adjusted EBITDA of $450 million-$600 million.
- It expects FY26 adjusted EPS of $3.10-$3.60 and Adjusted EBITDA of $800 million-$950 million.
- Price Action: FLR shares traded lower by 1.39% at $27.00 on the last check Friday.
Related Posts
Vitalik Buterin Says He’s Still Poorer Than Sam Bankman-Fried After FTX CEO’s Net Worth Goes Up In Smoke
Ethereum (CRYPTO: ETH) co-founder Vitalik Buterin said that he is still
Elon Musk, Sam Altman, Grimes, Jensen Huang Are Among Time Magazine’s Top Artificial Intelligence Voices
Among the hottest topics of 2023 has been the rise of artificial intelligence (AI), especially since the valuations of public and private companies involved in the sector have surged.
A new list highlights the top 100 people in the field and it includes some recognizable names. Here are some highlights.
Reported Late Wednesday March 22, Cidara Therapeutics And Melinta Therapeutics Announce FDA Approval Of REZZAYO For The Treatment Of Candidemia And Invasive Candidiasis
– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options –
– REZZAYO